Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Adult
Aged
Biomarkers, Tumor
Computational Biology
/ methods
DNA Copy Number Variations
Female
Gene Expression Profiling
/ methods
Genes, Neoplasm
Genomics
/ methods
High-Throughput Nucleotide Sequencing
Humans
Male
Middle Aged
Molecular Targeted Therapy
Mutation
Neoplasms
/ diagnosis
Prognosis
Treatment Outcome
NCC Oncopanel
actionable gene aberration
clinical sequencing
gene panel test
insurance reimbursement
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
24
09
2018
revised:
21
01
2019
accepted:
06
02
2019
pubmed:
12
2
2019
medline:
17
4
2019
entrez:
12
2
2019
Statut:
ppublish
Résumé
Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer-related societies. Twenty-five (13.3%) cases have since received molecular-targeted therapy according to their gene aberrations. These results indicate the utility of tumor-profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141).
Identifiants
pubmed: 30742731
doi: 10.1111/cas.13969
pmc: PMC6447843
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1480-1490Subventions
Organisme : National Cancer Center Research and Development Fund
ID : 27-A-1, 30-A-6
Organisme : Japan Agency for Medical Research and Development
ID : JP18kk0205004, JP18lk1403003
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Nat Med. 2014 Nov;20(11):1220-1
pubmed: 25375911
Cancer Sci. 2017 Jul;108(7):1440-1446
pubmed: 28440963
Genome Med. 2018 Jun 7;10(1):44
pubmed: 29880027
Clin Pharmacol Ther. 2016 Dec;100(6):626-632
pubmed: 27618128
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
JCO Precis Oncol. 2018 Nov;2:1-24
pubmed: 35135139
J Natl Cancer Inst. 2006 Dec 20;98(24):1760-3
pubmed: 17179473
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cancer Sci. 2019 Apr;110(4):1480-1490
pubmed: 30742731
Cancer Res. 2015 Jun 1;75(11):2264-71
pubmed: 25855381
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Cancer Discov. 2016 Apr;6(4):430-45
pubmed: 26603525
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Nat Med. 2012 Mar 18;18(4):521-8
pubmed: 22426421
Cancer Cell. 2019 Feb 11;35(2):177-190.e8
pubmed: 30686770
Oncotarget. 2017 Jun 20;8(25):41474-41486
pubmed: 28467813
Neoplasia. 2015 Apr;17(4):385-99
pubmed: 25925381
Cancer Sci. 2018 Mar;109(3):507-512
pubmed: 29285848
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
pubmed: 20952405
Cancer Sci. 2018 Sep;109(9):2980-2985
pubmed: 30187675
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Bioinformatics. 2011 Sep 15;27(18):2601-2
pubmed: 21803805
Hum Genet. 2018 Jan;137(1):31-37
pubmed: 29128982
Nature. 2017 Oct 5;550(7674):128-132
pubmed: 28953875
Mol Cancer. 2016 Nov 16;15(1):73
pubmed: 27852271
Am J Clin Pathol. 2015 Oct;144(4):667-74
pubmed: 26386089
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Curr Opin Genet Dev. 2017 Feb;42:56-67
pubmed: 28391084
Nat Rev Drug Discov. 2016 May 3;15(5):293-4
pubmed: 27139984
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Cancer Sci. 2016 Jun;107(6):713-20
pubmed: 27027665
Hum Genome Var. 2015 Nov 26;2:15050
pubmed: 27081555
Oncotarget. 2017 Dec 29;9(5):6228-6237
pubmed: 29464067
Lancet Oncol. 2015 Mar;16(3):251-2
pubmed: 25752548
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570
Genet Med. 2017 Feb;19(2):249-255
pubmed: 27854360